Supreme Court: Air Force Group Insurance Society qualifies as ‘State’ under Article 12 || SC: Anganwadi Workers With Degrees Are Eligible For The 29% Quota For Supervisors in Kerala || SC: Giving Accused the Option of Search Before a Police Officer Breaches Section 50 of the NDPS Act || Gujarat HC: Person is Entitled to Compensation For Injury or Death Within Railway Station Premises || Delhi HC: PMLA Can Apply Even if the Scheduled Offence Occurred Before the Law Came Into Force || J&K&L HC: Accused Can Admit Evidence Recorded under Section 299 Crpc After Appearing in Court || J&K&L HC: District Judge Serving as Reference Court under Land Acquisition Act Acts as a Civil Court || Del HC: Subsequent Bail Pleas From Same FIR Should Usually Go Before the Judge Who Denied the First || J&K&L HC: Vaishno Devi Shrine Board, Despite Statutory Status, is Not a ‘State’ under Article 12 || SC: Confirmation of an Auction Sale Does Not Bar Judicial Scrutiny of Reserve Price Valuation

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :